Brussels, 18/02/2005 (Agence Europe) - The European organisation of associations working on rare diseases (EURORDIS) has published its position on the European draft regulation to ensure child suitable medicines are developed.
EURORDIS supports the Commission's draft regulation (see EUROPE of 29 September and 1 October 2004), particularly the measure foreseeing a two year extension (from 10 to 12 years) in the length of time a medicine is protected once the laboratory producing it has...